The stages of type 1A diabetes: 2005

被引:87
|
作者
Gianani, R [1 ]
Eisenbarth, GS [1 ]
机构
[1] Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA
关键词
D O I
10.1111/j.0105-2896.2005.00248.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Type 1A diabetes is a chronic autoimmune disease usually preceded by a long prodrome during which autoantibodies to islet autoantigens are present. These antibodies are directed to a variety of antigens, but the best characterized are glutamic acid decarboxylase-65, insulinoma-associated antigen-2, and insulin. We hypothesize that the natural history of type 1A diabetes can be represented by several stages, starting from genetic susceptibility and ending in complete beta-cell destruction and overt diabetes. Type 1A diabetes probably results from a balance between genetic susceptibility and environmental influences. In both humans and animal models, the major determinants of the disease are genes within the major histocompatibility complex. The next best-characterized susceptibility locus is the insulin gene, the variable nucleotide tandem repeat locus. This gene affects the expression of insulin in the thymus and thus may play a role in the modulation of tolerance to this molecule. In a subset of genetically susceptible individuals, the activation of autoimmunity may be triggered by environmental factors such as viruses and/or diet. However, no conclusive association has been established between type 1A diabetes and specific environmental triggers. In this review, we provide evidence that insulin has a fundamental role in anti-islet autoimmunity.
引用
收藏
页码:232 / 249
页数:18
相关论文
共 50 条
  • [21] Primary prevention of type 1A diabetes: are we there yet?
    Barker, Jennifer M.
    Eisenbarth, George S.
    PEDIATRIC DIABETES, 2007, 8 (03) : 115 - 116
  • [22] Immunologic "vaccination" for the prevention of autoimune diabetes (type 1A)
    Simone, EA
    Wegmann, DR
    Eisenbarth, GS
    DIABETES CARE, 1999, 22 : B7 - B15
  • [23] Diabetes in a Patient with Glycogen Storage Disease Type 1a
    Kanemaru, Yoshinori
    Harada, Norio
    Wada, Naoki
    Yasuda, Takuma
    Okamura, Emi
    Fujii, Toshihito
    Ogura, Masahito
    Inagaki, Nobuya
    INTERNAL MEDICINE, 2024, 63 (15) : 2153 - 2156
  • [24] A glycogen storage disease type 1a patient with type 2 diabetes
    Yi Sun
    Wenhui Qiang
    Runze Wu
    Tong Yin
    Jie Yuan
    Jin Yuan
    Yunjuan Gu
    BMC Medical Genomics, 15
  • [25] A glycogen storage disease type 1a patient with type 2 diabetes
    Sun, Yi
    Qiang, Wenhui
    Wu, Runze
    Yin, Tong
    Yuan, Jie
    Yuan, Jin
    Gu, Yunjuan
    BMC MEDICAL GENOMICS, 2022, 15 (01)
  • [26] Trends in cost of prescription medication by stages of diabetic nephropathy in patients with type 1 diabetes between 1995 and 2005
    Lithovius, R.
    Harjutsalo, V.
    Saraheimo, M.
    Forsblom, C.
    Groop, P. -H.
    DIABETOLOGIA, 2011, 54 : S442 - S442
  • [27] Class II peptide multimers: promise for type 1A diabetes?
    Eisenbarth, GS
    Nepom, GT
    NATURE IMMUNOLOGY, 2002, 3 (04) : 344 - 345
  • [28] Class II peptide multimers: promise for type 1A diabetes?
    George S. Eisenbarth
    Gerald T. Nepom
    Nature Immunology, 2002, 3 : 344 - 345
  • [29] Predisposition, early stages and phenotypes of type 1 diabetes
    Achenbach, P.
    Winkler, C.
    Haupt, F.
    Beyerlein, A.
    Ziegler, A. -G.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 (21) : 1100 - 1104
  • [30] Early Detection at Different Stages of Type 1 Diabetes
    Wabitsch, M.
    Birkenfeld, A. L.
    Danne, T.
    Holder, M.
    Ziegler, R.
    DIABETES STOFFWECHSEL UND HERZ, 2024, 33 (05):